Trial Profile

Phase I Clinical Study on the Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 11 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Depoxythilone (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Carcinoma; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Testicular cancer
Focus Adverse reactions; First in man
Sponsors BioStar Pharmaceuticals

03 Sep 2024 Status changed from recruiting to active, no longer recruiting, According to a BioStar Pharmaceuticals media release,
03 Sep 2024 According to a BioStar Pharmaceuticals media release, company announce subject recruitment has been completed.
04 Jun 2024 Results (As of 22nd January 2024, n=10) assessing the tolerability, safety, and efficacy of utidelone in advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com